Identifying brain connectivity changes in Alzheimer's disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project aims to determine if changes in brain connectivity can predict the development of Alzheimer's disease. The study will involve six specific objectives, including identifying brain connectivity changes in individuals with abnormal AD biomarkers, assessing correlations with synaptic dysfunction and inflammation, and evaluating the impact of treatments like cholinesterase inhibitors and statins. Additionally, it will explore the relationship between brain connectivity and cognitive decline, as well as the presence of microorganisms in cerebrospinal fluid. Neuroimaging techniques will be utilized to gather data.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Inclusion criteria for subjects with subjective cognitive complaints:

   * MMSE (Mini-mental test) or MoCA (Montreal Cognitive Assessment) points between 26 and 30.
   * Absence of cognitive impairment.
   * Memory problems reported by the participant/family member.
   * Do not fulfill criteria for mild cognitive impairment or dementia.
   * Must speak and understand Swedish.
2. Inclusion criteria for patients with mild cognitive impairment:

   * MMSE (Mini-mental test) or MoCA (Montreal Cognitive Assessment) points between 24 and 30.
   * Impaired memory function.
   * Do not fulfill criteria for dementia.
   * Must speak and understand Swedish.
   * Must have abnormal cerebrospinal fluid amyloid-β 42/40 ratio levels, which is a biomarker of Alzheimer's disease.
3. Specific inclusion criteria for patients with Alzheimer's disease:

   * MMSE (Mini-mental test) or MoCA (Montreal Cognitive Assessment) points between 18 and 28.
   * Impaired memory function in addition to impaired executive abilities, language function, visuospatial ability and/or attention/psychomotor speed.
   * Meet NINCDS-ADRDA and DSM-IV criteria for probable Alzheimer's disease.
   * Must speak and understand Swedish.
   * Must have abnormal spinal fluid amyloid-β 42/40 ratio levels, which is a biomarker of Alzheimer's disease.

Exclusion Criteria:

* Alcohol or drug abuse.
* Unstable somatic disease or organ failure.
* Refuse to cerebrospinal fluid testing and/or blood sampling, neuropsychological testing, brain imaging, electroencephalogram or magnetoencephalogram.

In addition, participants who have claustrophobia or some form of metal implant in their body that may interfere with the brain imaging scan will be excluded from the study.

Where it's running

• Karolinska University Hospital
  Stockholm, Solna, Sweden Recruiting

Study contacts

• Study coordinator: Joana B. Pereira, PhD
• Email: joana.pereira@ki.se
• Phone: +46709966186

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Blood biomarker cohort for memory disorders in older adults

  This observational cohort will collect blood samples and brain imaging data from adults 50+ with memory disorders and a small group of healthy young adults to help find biomarkers.

  Recruiting Yonsei University · Seoul, Seodamun-gu · NCT07880275

• Tau changes after hip or knee replacement surgery

  Researchers will see if brain tau changes after hip or knee surgery and whether these changes relate to inflammation and thinking abilities.

  Recruiting Uppsala University Hospital · Uppsala · NCT07871487

• Low-Dose Whole-Brain Radiation Therapy With HeLaXON 1X in Mild Alzheimer's Dementia

  This study will test whether a low-dose brain radiation treatment using HeLaXON helps people with mild Alzheimer's dementia improve or stabilize thinking and daily function.

  Recruiting ReadyCure Inc. · Cheonan, Chungcheongnam-do · NCT07863011

• Cervical lymphatic surgery to see if it helps people with mild Alzheimer’s

  We’re testing a surgical approach in people with mild Alzheimer’s to see if creating alternative neck lymph drainage routes can affect brain biomarkers and daily function.

  Recruiting at 2 sites Maliszewski Daniel · Gdansk and 1 other locations · NCT07857759

• Transcranial random noise stimulation for behavioral and psychological symptoms in Alzheimer's disease

  This trial tests whether high-frequency transcranial random noise stimulation can help people with early Alzheimer's disease who have BPSD, compared to a sham treatment.

  Recruiting Anhui Medical University · Hefei, Anhui · NCT07827196

• Testing LY4405094 in healthy people and people with Alzheimer’s disease

  This study tests LY4405094 to see if it is safe and how it behaves in the body, including how it reaches the brain fluid in healthy participants and how it affects a brain protein in people with Alzheimer's disease.

  Recruiting Phase 1 Eli Lilly and Company · Anaheim, California and 17 other locations · NCT07787182

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.